Pharmacokinetics of 'party pill' drug N-benzylpiperazine (BZP) in healthy human participants

Forensic Science International

Volumn 186, Issue 1-3, 2009, Pages 63-67

  Antia, U ^a   Lee, H S ^a   Kydd, R R ^a   Tingle, M D ^a   Russell, B R ^a  

^a UNIVERSITY OF AUCKLAND   (New Zealand)

Author keywords

BZP; Metabolites; Pharmacokinetics; Plasma; Urine

Indexed keywords

N BENZYLPIPERAZINE; PIPERAZINE; RECREATIONAL DRUG; UNCLASSIFIED DRUG;

ADULT; ARTICLE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG URINE LEVEL; HUMAN; HUMAN EXPERIMENT; MALE; NORMAL HUMAN; PRIORITY JOURNAL;

EID: 62549160855     PISSN: 03790738     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.forsciint.2009.01.015     Document Type: Article

References (15)

1. Meririnne E., Kajos M., Kankaanpaa A., and Seppala T. Rewarding properties of 1-benzylpiperazine, a new drug of abuse, in rats. Basic & Clinical Pharmacology & Toxicology 98 4 (2006) 346-350
2. Antia U. Metabolism of party pill drug - TFMPP. ASCEPT NZ Scientific Meeting. Auckland, New Zealand (2007)
3. M. Murphy, U. Antia, H. Chang, J. Han, A. Ibrahim, B. Russell, et al., Party pills and drug-drug interactions, New Zealand Medical Journal, in press.
4. Tsutsumi H., Katagi M., Miki A., Shima N., Kamata T., Nishikawa M., et al. Development of simultaneous gas chromatography - mass spectrometric and liquid chromatography - electrospray ionisation mass spectrometric determination method for the new designer drugs, N-benzylpiperazine (BZP), 1-(3-trifluoromethylphenyl)piperazine (TFMPP) and their main metabolites in urine. Journal of Chromatography B 819 (2005) 315-322
5. Staack R., Fritschi G., and Maurer H. Studies on the metabolism and toxicological detection of the new designer drug N-benzylpiperazine in urine using gas chromatography-mass spectrometry. Journal of Chromatography B 773 (2002) 35-46
6. Gordon M., Millar J., Kirk I., Lim V., Waldie K., and Russell B. The effects of benzylpiperazine (BZP) administration on the Poffenberger paradigm of interhemispheric transfer in healthy adult right handed males. Australasian Winter Conference on Brain Research. Queenstown, New Zealand (2007)
7. Lee H., Gordon M., Millar J., Kirk I., Lim V., and Russell B. The acute effects of trifluoromethylphenylpiperazine (TFMPP) administration on the amplitude of the P300 in healthy adult right handed human males. Australasian Winter Conference on Brain Research. Queenstown, New Zealand (2007)
8. Russell B., Gordon M., Millar J., Kirk I., Lim V., and Waldie K. Benzylpiperazine (BZP) decreases the amplitude of the P300 event-related potential (ERP) in healthy adult right-handed human males. Australasian Winter Conference on Brain Research 2007. Queenstown, New Zealand (2007)
9. Bye C., Munro-Faure A., Peck A., and Young P. A comparison of the effects of 1-benzylpiperazine and dexamphetamine on human performance tests. European Journal of Clinical Pharmacology 6 (1973) 163-169
10. Campbell H., Cline W., Evans M., Lloyd J., and Peck A. Comparison of the effects of dexamphetamine and 1-benzylpiperazine in former addicts. European Journal of Clinical Pharmacology 6 (1973) 170-176
11. Fantegrossi W., Winger G., Woods J., Woolverton W., and Coop A. Reinforcing and discriminative stimulus effects of 1-benzylpiperazine and triflouromethylphenylpiperazine in rhesus monkeys. Drug and Alcohol Dependence 77 (2005) 161-168
12. P. Gee, S. Richardson, W. Woltersdorf, G. Moore. Toxic effects of BZP-based herbal party pills in humans: a prospective study in Christchurch, New Zealand, The New Zealand Medical Journal, 118 (2005) U1784 (accessed online).
13. U. Antia, M. Tingle, B. Russell. Validation of an LC-MS method for the detection and quantification of BZP and TFMPP and their hydroxylated metabolites in human plasma. Forensic Science International (2008) (in review).
14. Tsutsumi H., Katagi M., Miki A., Shima N., Kamata T., Nakajima K., Inoue H., Kishi T., Tsuchihashi H., et al. Metabolism and the urinary excretion profile of the recently scheduled designer drug N-benzylpiperazine (BZP) in the rat. Journal of Analytical Toxicology 30 (2006) 38-43
15. Harris D.S., Boxenbaum H., Everhart E.T., Sequeira G., Mendelson J.E., and Jones R.T. The bioavailability of intranasal and smoked methamphetamine. Clinical Pharmacology and Therapeutics 74 (2003) 475-486